Top

Published in:

01-06-2009 | PHASE I STUDIES

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

Authors: Michael Michael, Peter Gibbs, Robert Smith, Alex Godwood, Stuart Oliver, Niall Tebbutt

Published in: Investigational New Drugs | Issue 3/2009

Summary

Background: Vandetanib (ZACTIMA™) is a once-daily oral inhibitor of vascular endothelial growth factor, epidermal growth factor and RET receptor tyrosine kinases. The safety and tolerability of vandetanib plus mFOLFOX6 was investigated in patients with advanced colorectal cancer (CRC). Methods: Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of mFOLFOX6. Results: Seventeen patients received vandetanib 100 mg (n = 9) or 300 mg (n = 8) plus mFOLFOX6. The protocol definition of a tolerable dose (vandetanib-related dose-limiting toxicity [DLT] in less than two patients) was met in both dose cohorts, with one DLT of diarrhoea reported in each. Overall, the most common adverse events were diarrhoea, nausea and lethargy (all n = 11). There was no pharmacokinetic interaction between vandetanib and mFOLFOX6. Preliminary efficacy results included one complete response and three confirmed partial responses. Conclusions: In patients with advanced CRC, once-daily vandetanib (100 or 300 mg) with mFOLFOX6 was generally well tolerated.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676. doi:10.1038/nm0603-669 CrossRefPubMed

Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36:748–753. doi:10.1016/S0959-8049(00)00003-4 CrossRefPubMed

Tokunaga T, Oshika Y, Abe Y et al (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77:998–1002PubMed

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi:10.1056/NEJMoa032691 CrossRefPubMed

Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. doi:10.1200/JCO.2007.14.9930 CrossRefPubMed

Mayer A, Takimoto M, Fritz E et al (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454–2460. doi:10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2 CrossRefPubMed

Tabernero J, Van Cutsem E, Diaz-Rubio E et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225–5232. doi:10.1200/JCO.2007.13.2183 CrossRefPubMed

Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345. doi:10.1056/NEJMoa033025 CrossRefPubMed

Van Cutsem E, Nowacki M, Lang I et al (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 25(18S):4000

10.

Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561. doi:10.1200/JCO.2007.12.0949 CrossRefPubMed

11.

Punt CJ, Tol J, Rodenburg CJ et al (2008) Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(15S):LBA4011

12.

Hecht JR, Mitchell E, Chidiac T et al (2008) An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/− panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). American Soc Clin Oncol GI Cancers Symposium: abst 273

13.

Wedge SR, Ogilvie DJ, Dukes M et al (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645–4655PubMed

14.

Ichihara M, Murakumo Y, Takahashi M (2004) RET and neuroendocrine tumors. Cancer Lett 204:197–211. doi:10.1016/S0304-3835(03)00456-7 CrossRefPubMed

15.

Holden SN, Eckhardt SG, Basser R et al (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391–1397. doi:10.1093/annonc/mdi247 CrossRefPubMed

16.

Tamura T, Minami H, Yamada Y et al (2006) A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1:1002–1009. doi:10.1097/01243894-200611000-00014 CrossRefPubMed

17.

Natale RB, Bodkin D, Govindan R et al (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized Phase II trial. J Clin Oncol 24(18S):abst 7000

18.

Heymach JV, Johnson BE, Prager D et al (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25:4270–4277. doi:10.1200/JCO.2006.10.5122 CrossRefPubMed

19.

Heymach J, Paz-Ares L, de Braud F et al (2007) Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25(18S):abst 7544

20.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205 CrossRefPubMed

21.

Cascinu S, Berardi R, Salvagni S et al (2008) A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 98:71–76. doi:10.1038/sj.bjc.6604121 CrossRefPubMed

22.

Messersmith WA, Laheru DA, Senzer NN et al (2004) Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10:6522–6527. doi:10.1158/1078-0432.CCR-04-0746 CrossRefPubMed

23.

Wolpin BM, Clark JW, Meyerhardt JA et al (2006) Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer 6:208–213. doi:10.3816/CCC.2006.n.037 CrossRefPubMed

24.

Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147PubMed

25.

Chen E, Jonker D, Maclean M et al (2006) Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group. EJC Supplements 4(12):abst 93

26.

Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544. doi:10.1200/JCO.2006.09.6305 CrossRefPubMed

27.

Thomas AL, Trarbach T, Bartel C et al (2007) A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol 18:782–788. doi:10.1093/annonc/mdl469 CrossRefPubMed

28.

Graham MA, Lockwood GF, Greenslade D et al (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205–1218PubMed

29.

Takimoto CH, Yee LK, Venzon DJ et al (1999) High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res 5:1347–1352PubMed

30.

Izzedine H, Rixe O, Billemont B et al (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203–218. doi:10.1053/j.ajkd.2007.04.025 CrossRefPubMed

31.

Abhyankar VV, Sharma S, Trowbridge RC et al (2008) Axitinib (AG-013736) in combination with FOLFOX and bevacizumab (Bev) in patients (pts) with metastatic solid tumors: A phase I study. J Clin Oncol 26(15S):abst 4112

32.

Kupsch P, Henning BF, Passarge K et al (2005) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188–196. doi:10.3816/CCC.2005.n.030 CrossRefPubMed

Title: Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
Authors: Michael Michael
Peter Gibbs
Robert Smith
Alex Godwood
Stuart Oliver
Niall Tebbutt
Publication date: 01-06-2009
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2009
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-008-9182-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2009

Hesperetin exerts dose dependent chemopreventive effect against 1,2-dimethyl hydrazine induced rat colon carcinogenesis

Publication biases and phase II trials investigating anticancer targeted therapies

Rhinitis and epistaxis in patients treated by anti-angiogenic therapy

Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis

Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer